Experimental lymphoma combo trial halted early

NCT ID NCT04425070

First seen Jan 10, 2026 · Last updated May 09, 2026 · Updated 18 times

Summary

This study tested a drug called selinexor combined with chemotherapy or another drug (tislelizumab) in 56 adults with relapsed or hard-to-treat T-cell or NK-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, 230031, China

  • Beijing Tongren Hospital.CMU

    Beijing, Beijing Municipality, 100005, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, 530021, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450008, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, 210000, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

  • Tianjin Medical Universisity Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300060, China

Conditions

Explore the condition pages connected to this study.